Tesaro licenses cancer technology from Amgen

03/23/2011 | Mass High Tech (Boston)

Amgen agreed to exclusively license its anaplastic lymphoma kinase technology to Tesaro to help develop drugs for nonsmall-cell lung cancer. The deal calls for Tesaro to pay upfront and milestone fees to Amgen in exchange for development, production and marketing rights to ALK small-molecule drugs.

View Full Article in:

Mass High Tech (Boston)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide